Document is current
Any future updates will be listed below
-
Authors
Olson, Daniel J
Larkin, James
Hong, Young
Thomas, Sajeve
Martin-Liberal, Juan
Furness, Andrew JS
Terheyden, Patrick
In, Gino K
Poklepovic, Andrew S
Samhouri, Yazan
Lammers, Philip
Atkinson, Victoria
Nguyen, Ryan H
Peretz, Idit
Butler, Marcus
Finckenstein, Friedrich Graf
Chou, Jeffrey
Wu, Xiao
Sulur, Giri
Shi, Wen
Haanen, John B
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05727904 at ClinicalTrials.govDocuments that mention this clinical trial
778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma
https://doi.org/10.1136/jitc-2023-sitc2023.0778
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
https://doi.org/10.1200/jco.2023.41.16_suppl.tps9607
- License Information
